NA Proactive news snapshot: TRACON Pharmaceuticals, Mawson Gold, KULR Technology, Calyxt ...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) reported second-quarter financial results after the market closed on Wednesday that showed it has enough funds to carry out a pivotal trial of single-domain antibody envafolimab as a treatment for sarcoma cancers. San Deigo-based TRACON said it expects to initiate enrollment in the ENVASARC trial evaluating envafolimab in the fourth quarter. It will be evaluate envafolimab’s effectiveness in treating undifferentiated pleomorphic sarcoma (UPS), a rare type of cancer that begins in the soft tissues, and myxofibrosarcoma (MFS), a cancer that appears as a painless lump on legs or arms. The company said it had cash and equivalents of $14.5 million as of June 30, 2020. Mawson Gold Limited (TSE:MAW) (OTCPINK:MWSNF), previously called Mawson Resources, is to joint venture its permitted and drill-ready Western USA epithermal gold project (WUSA) to Aguila American Gold Ltd (Aguila). In a statement, the junior explorer, said it has inked a letter of intent (LOI) over a deal, whereby Aguila will invest US$1.2 million in the project to earn up to an 80% interest. Mawson will hold a 20% non-dilutable position until a decision to mine, and will be free carried by loans from Aguila, repayable from production cash flows, it told investors. KULR Technology Group Inc (OTCQB:KULR) revealed on Thursday that the US Patent Office has awarded it a patent for its Fiber Thermal Interface (FTI), a highly flexible and compressible high-performance thermally conductive carbon fiber material developed for a variety of different applications, including space, automotive, and electronics industries. The Campbell, California-based company’s FTI technology is a carbon fiber solution that is part of KULR’s space-proven thermal architecture. The company said it offers “superior thermal conductivity, ultra-lightweight and flexible mechanical properties designed for space exploration and applications” where efficient cooling, size and weight restrictions are paramount. Calyxt Inc (NASDAQ:CLXT), a plant-based technology company, posted second-quarter results on Thursday that revealed s dramatic revenue increase and a ramping up in plant volumes. The company reported revenue of $2.3 million for the three months ended June 30, 2020, more than five times greater than its revenue in the same period of 2019. That jump was driven primarily by higher sales volumes, which included a purchase of 300,000 bushels of soybeans from one of the world’s largest processors. Mind Medicine (MindMed) Inc. (OTCQB:MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic-assisted therapy expert Dr Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy. Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland. He has served as the President of the Swiss Medical Society for Psycholytic Therapy since 1997. Benchmark Metals Inc (CVE:BNCH) (OTCQB:CYRTF) has reported very encouraging drill assays from a hole at its flagship Lawyers gold-silver project in British Columbia, which augurs well for the potential resource at the Cliff Creek area. The hole was sunk at a zone of limited historical drilling east of the Cliff Creek main zone and outside of the modeled mineralization, the company noted. From surface, it hit broad mineralization and yielded 57.91 metres (m) of 1.90 grams per tonne (g/t) gold and 91.96 g/t silver or 3.05 g/t gold equivalent. Within this, were higher-grade intervals include 33.53 metres of 3.17 g/t gold and 152.28 g/t silver or 5.07 g/t gold equivalent. Information Services Corporation (TSE:ISV) delivered C$31 million in revenue during its second-quarter 2020 in what CEO Jeff Stusek called a “relatively strong” performance driven by cost management throughout the coronavirus pandemic. The Regina, Saskatchewan-based firm, which provides registry and information management services for public data and records, saw transactions return to normal in its Services segment but experienced lower transaction volumes in its Registry Operations division as consumers held back on big-ticket purchases like homes and cars. Humanigen, Inc. (OTCQB:HGEN), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab has announced the appointment of Bob Atwill, to the newly created role of Head of Asia-Pacific, effective immediately.  Atwill will report to Dr Cameron Durrant, Humanigen’s chief executive officer of and will initially serve on a consultancy basis. Atwill has more than 30 years of experience in the global healthcare industry across the pharmaceutical, biotechnology and cellular therapy sectors. He began his career at GlaxoSmithKline and Sanofi-Synthélabo prior to holding senior executive and consulting roles at Mesoblast, Benitec Biopharma and a number of other US, European and Australian-listed biotechnology companies. He currently serves as Principal at Eaton Square, a cross-border M&A and capital service provider, in its biotechnology practice, based in the Melbourne office. Steppe Gold Ltd. (TSX:STGO), Mongolia's premier precious metals company, has announced that the previously announced C$15 million investment in the company by renowned Canadian resources investor Eric Sprott has been completed. Sprott, through 2176423 Ontario Ltd., a corporation beneficially owned by him, acquired a total of 6,976,944 units in Steppe Gold at a price of C$2.15 per unit. The net proceeds of the investment will be used by the company to advance their exploration and development projects as well as for working capital and general corporate purposes. Great Panther Mining Limited (TSE:GPR) (NYSEAMERICAN:GPL), the precious metals miner, posted a clutch of record numbers in its second quarter financials, despite the challenges posed by the coronavirus pandemic, including a net income compared to a loss in the same period last year. The group put the strong results down to the strong rise in the gold price and record output from its flagship Tucano mine in Brazil. Net income for the three months to June 30 came in at a record US$8.5 million compared to a loss of US$5.7 million for the second quarter of 2019. The Flowr Corporation (CVE:FLWR) (OTCMKTS:FLWPF) has closed another round of funding under its agreement with Terrace Global to fund its outdoor medical cannabis site in Portugal. The facility in Aljustrel is jointly operated with Terrace Global (CVE:TRCE), a Canadian company focused on the development and acquisition of international cannabis assets. Under the second tranche, Flowr will receive C$500,000 as part of the equity line and profit share agreement with Terrace, which will fund the operations and certain expenditures at Aljustrel in exchange for a stake in Flowr. Antibe Therapeutics Inc. (CVE:ATE) (OTCQB:ATBPF) said it has engaged Stern Investor Relations, Inc. to expand the company’s investor relations program and support efforts to broaden visibility within the US capital markets. In a statement, Dan Legault, CEO of Antibe commented: “We are excited to have engaged Stern IR as our new investor relations firm to support us in enhancing our visibility within the US clinical and financial communities.” Under the terms of the agreement, Stern IR will provide strategic advisory and comprehensive investor relations services for an initial six-month term, at a fee of US$17,500 per month. Subsequent to the initial term, the engagement will continue on a month-to-month basis and can be terminated by either party on 60 days prior notice. The agreement is subject to acceptance by the TSX Venture Exchange. PUDO Inc. (CSE:PDO) (OCTQB:PDPTF), North America's only carrier-neutral parcel pick-up and drop-off network has confirmed, in response to a request by the Investment Industry Regulatory Organization of Canada that company management is unaware of any material change in the group's operations that would account for the recent increase in market activity. Viscount Mining Corp (CVE:VML) said the TSX Venture Exchange has accepted for filing documentation with respect to its non-brokered private placement announced on July 29, 2020, which will see the issue of 23,958,332 shares at a purchase price of 24 cents per share, together with 23,958,332 share purchase warrants at an initial exercise price of 32 cents and a term to expiry of two years with 116 placees. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has announced that its chief executive officer, Armando Amido will present a company overview at the virtual 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Wednesday, August 12, 2020, at 4.30pm EDT. The meeting is being held virtually, and a live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com. Phunware, Inc. (NASDAQ:PHUN), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, has announced that it will be presenting next week at the 40th Annual Growth Conference hosted by Canaccord Genuity. Due to the ongoing coro0navirus (COVID-19) pandemic, the conference will be held virtually this year from August 11-13, 2020. Phunware President, CEO and Co-Founder, Alan S. Knitowksi, will present on Thursday, August 13, at 8.00am CT / 9.00am. ET. Following the presentation, the Phunware Executive Team will be available for virtual one-on-one meetings throughout the day.